Cytotoxic chemotherapy administered to two patients with partially refractory leukaemia while receiving intensive care treatment

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
K A Al-Anazi, S Jacobs

Abstract

Administration of cytotoxic chemotherapy to a mechanically ventilated patient is a major undertaking. Induction of remission of leukaemia under such circumstances is an extremely rare event. We report two patients with partially refractory acute myeloid leukaemia who achieved remission of their leukaemia after receiving chemotherapy in the intensive care unit. Both patients were subsequently cured by allogeneic bone marrow transplant.

References

Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Dec 1, 1985·Annals of Surgery·W A KnausJ E Zimmerman
Jan 1, 1994·Cancer Chemotherapy and Pharmacology·W J SlichenmyerR C Donehower
Jan 1, 1993·Cancer Treatment and Research·T G Woodworth, J C Nichols
Feb 1, 1993·Leukemia & Lymphoma·A SpadeaF Mandelli
Nov 26, 2002·Intensive Care Medicine·Michael DarmonBenoît Schlemmer
Jun 10, 2003·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Andrea A CogliatiGiovanni Rosa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.